Literature DB >> 29541214

Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer.

Kai Wang1, Chenan Guan2, Chenyan Fang3, Xiaoxiao Jin1, Junhui Yu1, Yuquan Zhang4, Lingzhi Zheng1.   

Abstract

Forkhead box (FOX) A1 is a member of the FOX family of transcription factors, which serve a function in numerous types of tumor. The present study assessed the potential role of FOXA1 in human epithelial ovarian carcinoma (EOC). Total RNA was isolated from 16 fresh-frozen EOC tumors with paired corresponding non-malignant ovarian epithelium tissues, and FOXA1 expression was analyzed using reverse transcription-quantitative polymerase chain reaction. Immunohistochemical analysis was performed to evaluate FOXA1 expression in 110 epithelial ovarian carcinoma tissue specimens (including 80 serous papillary adenocarcinoma, 9 clear cell carcinoma, 12 endometrioid adenocarcinoma, 5 mucinous carcinoma and 4 transitional cell carcinoma specimens), 24 benign ovarian tumor surface epithelium tissues and 10 normal ovarian tissue samples. The present study analyzed the association between FOXA1 expression and clinical characteristics in patients with EOC. The Kaplan-Meier method was used for survival analysis. The results of the present study revealed that FOXA1 mRNA expression was significantly increased in EOC tissues compared with paired normal ovarian samples (P=0.014). The immunohistochemical expression of FOXA1 in EOC tissues was associated with the FIGO grade, differentiation status and overall survival time (all P<0.05). Finally, the significance of FOXA1 expression in the prognosis of the patients was evaluated. The results of Kaplan-Meier survival curve revealed that high FOXA1 expression was associated with decreased overall survival time in the patients, relative to low FOXA1 expression (P=0.0132). In conclusion, FOXA1 is overexpressed in EOC and associated with clinicopathological features, including overall survival time. FOXA1 potentially represents a novel biomarker and therapeutic target for EOC.

Entities:  

Keywords:  Forkhead box A1; clinical significance; epithelial ovarian cancer; expression; prognostic value

Year:  2018        PMID: 29541214      PMCID: PMC5835846          DOI: 10.3892/ol.2018.7899

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Unified nomenclature for the winged helix/forkhead transcription factors.

Authors:  K H Kaestner; W Knochel; D E Martinez
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

3.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

4.  Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes.

Authors:  R H Costa; D R Grayson; J E Darnell
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 6.  Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.

Authors:  J C Schink
Journal:  Semin Oncol       Date:  1999-02       Impact factor: 4.929

7.  The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas.

Authors:  Lin Lin; Charles T Miller; Jorge I Contreras; Michael S Prescott; Susan L Dagenais; Rong Wu; John Yee; Mark B Orringer; David E Misek; Samir M Hanash; Thomas W Glover; David G Beer
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

8.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

9.  FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.

Authors:  Carmelo Nucera; Jerome Eeckhoute; Stephen Finn; Jason S Carroll; Azra H Ligon; Carmen Priolo; Guido Fadda; Mary Toner; Orla Sheils; Marco Attard; Alfredo Pontecorvi; Vânia Nose; Massimo Loda; Myles Brown
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

10.  Improved internal control for molecular diagnosis assays.

Authors:  T Vinayagamoorthy; Danielle Maryanski; Dilanthi Vinayagamoorthy; Katie S L Hay; Jacob Yo; Mark Carter; Joseph Wiegel
Journal:  MethodsX       Date:  2015-03-12
View more
  3 in total

1.  Transcriptome Analysis of Ovarian and Uterine Clear Cell Malignancies.

Authors:  Jill Alldredge; Leslie Randall; Gabriela De Robles; Anshu Agrawal; Dan Mercola; Marisa Liu; Pavneet Randhawa; Robert Edwards; Michael McClelland; Farah Rahmatpanah
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

2.  FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma.

Authors:  Tong Lou; Chongdong Liu; Hong Qu; Zhiqiang Zhang; Shuzhen Wang; Huiyu Zhuang
Journal:  J Transl Med       Date:  2022-01-06       Impact factor: 5.531

3.  High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer.

Authors:  Heba Sheta; Amal Abd El Hafez; Maha Saif; Alyaa R Elsergany; Doaa Al Emam; Mahmoud Mohamed Abdelrazik
Journal:  Pathologica       Date:  2021-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.